VENATORX PHARMACEUTICALS, INC. holds $44.4M across 6 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 12 offers. Set-aside status: NONE. Recompete timing centers on the Jan 18, 2027 PoP end — agencies typically plan 12–18 months ahead.
TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.
Current PoP ends Jan 18, 2027 (175 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Track recompete timing in SCOUT →VENATORX PHARMACEUTICALS, INC. — $44.4M obligated across 6 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open VENATORX PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →